In Vivo's Deals Of The Century: A Timeline
Executive Summary
When it comes to deal-making, In Vivo's editors have always been quick to single out transactions that we feel will spark trends or otherwise have a major impact on the life sciences industry. Below, an expandable timeline of the deals we chose as bellwethers for pharma and medtech in each year of this still-young century and what we said about them at the time. (Free article.)
Source Material From In Vivo's Archives
|
Date |
Article |
|
Sept. 2001 |
Inside Applera: Celera Genomics Becomes Applied Bio's Diagnostics Angel |
|
Oct. 2001 |
|
|
Oct. 2002 |
|
|
Feb. 2004 |
|
|
Jan. 2005 |
|
|
June 2006 |
|
|
Dec. 2006 |
How To Fix A Guidant: Boston Scientific's Tobin Opens Playbook |
|
Mar. 2007 |
Proteus Biomedical: Using Computers To Manage Chronic Diseases |
|
May 2007 |
|
|
June 2008 |
Royalty Flush: Why Monetizing Tomorrow's Revenue Stream Today Could Catch On In A Big Way |
|
Oct. 2008 |
Medtronic Strengthens Hand In Ablation Market With CryoCath Acquisition |
|
Jan. 2010 |
|
|
Dec. 2010 |
As Pfizer And UCSF Tighten Ties, More Deals With Academia Could Follow |
|
July 2011 |
|
|
Oct. 2011 |
|
|
Oct. 2012 |
|
|
Nov. 2012 |
A New Industry-Academic Model: Novartis And Penn Make A Splash In Cancer Immunotherapy |
|
Jul. 2014 |
When Illumina Buys Roche: The Dawning Of The Era Of Diagnostics Dominance |
|
Oct. 2014 |
GSK’s Venture Deal With Avalon Yields Three Start-Ups In Two Years |
|
Sept. 2015 |
In Buzz Of 2015 Pharma Dealmaking, Immuno-Oncology Is Queen Bee |
|
Jan. 2016 |
|
|
Dec. 2016 |